Both in Biotechnology
Relay Therapeutics vs Tarsus Pharmaceuticals
Over the past year RLAY returned +253.8% and TARS returned +32.0%; their daily moves had a correlation of 0.26.
RLAY +253.8% TARS +32.0%Growth of $1, one year, split-adjusted
| Metric | RLAY | TARS |
|---|---|---|
| Price | $18.36 | $76.69 |
| Market cap | $4.02B | $3.59B |
| Today | +3.79% | −0.16% |
| 1 month | −2.2% | +6.9% |
| 6 months | +96.4% | +14.6% |
| Year to date | +117.0% | −6.3% |
| 1 year | +255.1% | +36.2% |
| Revenue growth (YoY) | −48.3% | +69.4% |
| Gross margin | 100.0% | 93.0% |
| Net margin | −23916.3% | −10.7% |
| P/E (TTM) | — | — |
| Price / sales | 388.7× | 5.9× |
| Net cash | $910.9M | $376.9M |
| Dividend yield | — | — |
| Volatility (60d) | 44.5% | 54.0% |
| Short % of float | 28.2% | 16.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).